Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Sorafenib
Sponsor: SCRI Development Innovations, LLC
Collaborators: Bayer